
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026, 4:01 PM ET
Annexon reported third quarter 2026 results, with $213.4 million in cash as of September 30, 2026, expected to fund operations into 2028.
Nasdaq: $ANNXDated operating evidenceFinancing and capital structureExecution risk
ANNX Stock Hub: Annexon News, ARCHER II and GBS Filing
Annexon reported third-quarter 2026 results after the market close on November 9, 2026: a net loss of $51.2 million, or $0.25 per share, research and development expense of $41.4 million and $213.4 million of cash, cash equivalents and short-term investments at September 30, which the company expects to fund operations into 2028. The same release placed the U.S. tanruprubart BLA submission in the fourth quarter and kept the ARCHER II Month 15 committee assessment there, with sub-study results conditional on success and final Month 24 analyses guided to the third quarter of 2027. The stock closed at $4.23 on November 9, before the after-close release. Third-quarter 2026 release.
Full research report · PDF
Annexon ($ANNX), research as of November 9, 2026
15 pages covering the clinical and operating evidence, the third-quarter 2026 accounts, capital structure and scenarios described in this dated report This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next clinical catalyst
Q4 2026 · ARCHER II Month 15 assessment and tanruprubart BLA
Annexon guided the independent Data Monitoring Committee’s assessment of the ARCHER II overall Month 15 primary endpoint to the fourth quarter of 2026, and the U.S. Biologics License Application for tanruprubart, with U.S. and European FORWARD data, is anticipated in the same quarter while the European application remains under review. Third-quarter release · ARCHER II analysis plan
The November 3, 2026 investor event took place as scheduled and covered trial design, demographics and preparation for the results, not efficacy data. Sub-study analyses are expected in the first quarter of 2027 only if the Month 15 endpoint is met; otherwise the trial continues to the Month 24 endpoint, with completion guided to the third quarter of 2027.
ANNX stock at a glance
Close · November 9, 2026
$4.23
Regular-session close before the after-close release; up 0.71% on $4.20. Market value $806.9 million at 190,763,984 common shares, the count on the Form 10-Q cover as of November 5, 2026.
Liquidity · September 30, 2026
$213.4M
$102.4 million of cash and equivalents plus $111.0 million of short-term investments, against $209.2 million at June 30. Form 10-Q
Operating cash use, nine months
$143.5M
January to September 2026, against $140.4 million in the same period of 2025. Form 10-Q
Net loss · quarter to September 30, 2026
$51.2M
$0.25 per share on 204,652,743 weighted-average shares; research and development $41.4 million, general and administrative $10.9 million. Release
ARCHER II enrolment
659
Actual participants; all eligible patients past 15 months of treatment, retention 90%. Phase 3 registry
Guided runway
Into 2028
Company forecast, including $150 million of facility capacity subject to conditions Release
Where Annexon stands now
Third-quarter 2026 results, reported November 9 — what is new. Cash, cash equivalents and short-term investments were $213.4 million at September 30, against $209.2 million at June 30, after nine months of $143.5 million operating cash use, $66.2 million of net at-the-market proceeds and a $49.4 million term loan drawn in July. Current assets of $217.9 million against current liabilities of $37.7 million left positive working capital of $180.2 million, and the term loan was carried at $49.3 million. The quarter produced a net loss of $51.2 million, or $0.25 per share, on research and development expense of $41.4 million against $49.7 million a year earlier. Third-quarter release · Form 10-Q.
Programmes: two dated fourth-quarter events and one early-stage reset. The U.S. BLA for tanruprubart, with U.S. and European FORWARD data, is anticipated in the fourth quarter of 2026, while the European Marketing Authorisation Application filed in January 2026 remains under review. In ARCHER II all eligible patients have passed 15 months of treatment with retention at 90 per cent and masked vision-loss events tracking projections, and the committee assessment of the overall Month 15 endpoint is guided to the fourth quarter. The ANX1502 proof-of-concept study in nine patients with cold agglutinin disease is complete, with biomarker reductions and no significant safety signals, but formulation optimisation must improve absorption before studies in generalised myasthenia gravis. Programme update.
Financing still shapes the equity case. $115.2 million remained available under the 2026 at-the-market programme at September 30, and 639,068 further shares were sold for about $2.7 million after the quarter. Common shares outstanding were 190,763,984 on November 5, 2026, excluding 14,745,093 shares issuable on pre-funded warrants. The Oxford facility leaves $150.0 million available subject to milestone and lender conditions. Capital structure · Oxford facility.
Cash balances keep their reporting dates: the June figures remain the historical comparison, and the July borrowing sits in the September balance rather than the June one. The company’s runway statement combines existing resources with facility funds, so it is a planning forecast rather than an exhaustion date. Liquidity discussion.
The main constraint. The cash balance rose only because the company issued equity and drew debt: nine-month operating cash use of $143.5 million exceeded the $66.2 million raised through the at-the-market programmes. The runway into 2028 assumes access to conditional facility tranches, and a committee recommendation to continue to Month 24 would extend spending without resolving the efficacy question. The Form 10-Q also states that the FDA has indicated the generalizability package may not be sufficient to support BLA approval without additional patient data.
The constructive case
Replicated protection against vision loss could differentiate vonaprument clinically, while the GBS programme could provide a second late-stage opportunity, and a fourth-quarter BLA submission would put a first regulatory decision on the calendar. Successful milestones would strengthen the development case and potentially improve funding options.
The cautious case
The functional signal may not replicate, the Month 15 event may defer rather than resolve uncertainty, and regulators may require more evidence. Continued at-the-market sales at current prices, a larger share count and debt conditions constrain the equity case even with positive science.
Latest Annexon news
Nov 9, 2026
Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon reported third quarter 2026 financial results and business updates. Cash, cash equivalents and short-term investments were $213.4 million as of September 30, 2026, expected to fund operations into 2028. R&D expenses were $41.4 million for the quarter, compared to $49.7 million a year earlier, and G&A expenses were $10.9 million, compared to $7.3 million. The company entered a credit facility of up to $200 million with Oxford Finance LLC, drawing an initial $50 million at closing.
Nov 3, 2026
Annexon Phase 2 showed dose-dependent vision protection; ARCHER II 15-month analysis targeted for Q4 2026
Annexon's Phase 2 trial showed dose-dependent vision protection. The 15-month analysis of the ARCHER II trial is targeted for Q4 2026. Not confirmed by a company release or filing at the time of writing; to be verified.
Oct 28, 2026
Virtual investor event on November 3 will review the ARCHER II design, patient demographics and communication of upcoming results
Annexon will host a virtual investor event on Tuesday, November 3, 2026 at 11:00 a.m. ET on vonaprument for geographic atrophy and the Phase 3 ARCHER II trial. According to the release, management will discuss the trial design, patient demographics, the communication strategy for the anticipated 15-month and 24-month results beginning in the fourth quarter of 2026, and recent additions to the ophthalmology team. A retina specialist from Bay Area Retina Associates who is an ARCHER II clinical investigator will join management to discuss the unmet need and current treatment options. The event includes formal presentations and a live question-and-answer session, with registration through the link in the release. The announcement is a scheduled investor presentation, not a data release: it gives no ARCHER II efficacy results, and the Month 15 independent committee assessment remains guided to the fourth quarter of 2026. Press release
Oct 16, 2026
Inducement options for six new employees: 1,270,000 shares at $3.60
Annexon announced inducement options granted to six new non-executive employees under its 2022 Employment Inducement Award Plan, covering an aggregate of 1,270,000 shares. The options have a ten-year term and an exercise price of $3.60, the closing price on October 15, 2026, which the release identifies as the date of grant; the release also says the awards were approved on October 7, 2026. They vest over four years: 25% on the first anniversary of the grant date and 1/48th monthly thereafter. These are potential rights, not shares already issued, and carry no clinical information. Source
Sep 24, 2026
September 24: retinal meeting update
Baseline and earlier-study analyses provide context, not an ARCHER II efficacy result. [05]
Aug 12, 2026
August 12: ARCHER II endpoint expansion
Month 24 was added alongside Month 15, with staged DMC and sub-study analysis. [01]
ANNX stock catalysts and dated operating windows
- Q4 2026 — ARCHER II overall Month 15 DMC assessment, and the U.S. tanruprubart BLA submission with U.S. and European FORWARD data. Company guidance, November 9, 2026
- Q1 2027, conditional — ARCHER II sub-study analyses if the Month 15 overall endpoint is met. Conditional company guidance
- Q3 2027 — ARCHER II completion, including the Month 24 analyses. Company guidance
- November 9, 2026 · reported — third-quarter results: net loss of $51.2 million or $0.25 per share, cash and investments of $213.4 million, runway into 2028. Reported after the market close
- November 3, 2026 · held — virtual investor event on ARCHER II design, patient demographics and the communication of results. Held; presentation, not a data release
- Date not stated — ANX1502: proof-of-concept study complete in nine CAD patients; formulation optimisation under way before studies in generalised myasthenia gravis. Company plan
Third-quarter 2026 release · Form 10-Q · ARCHER II analysis plan
How to interpret the Month 15 announcement
An independent data monitoring committee, or DMC, will assess the overall primary endpoint at Month 15. The company expects to report the committee’s assessment during the fourth quarter. A recommendation that the overall study met the endpoint would permit the planned analyses of the two sub-studies, with those results expected later. A recommendation to continue to Month 24 would preserve the later assessment while leaving important uncertainty unresolved. [01]
This structure affects how much can reasonably be concluded from the first announcement. A favorable DMC assessment would be meaningful evidence, but it may not include the full effect size, subgroup detail, safety breakdown or complete statistical package needed for an independent investment evaluation. Readers should identify what has actually been disclosed and what remains pending, rather than filling the gaps with assumptions based on the tone of management’s comments.
Up to $200 million does not mean $200 million in the bank
Annexon entered an Oxford Finance facility in July 2026 with a maximum size of $200 million. The initial draw was $50 million. A further $100 million is tied to milestones, and another $50 million is subject to lender approval. Those distinctions are material: the full facility ceiling is not unrestricted cash available on demand. The initial borrowing occurred after June 30 and therefore was not part of that quarter-end balance; at September 30, 2026 the term loan was carried at $49.340 million and $150.0 million of borrowing capacity remained available, subject to specified conditions. Form 10-Q [07] [08]
The agreement provides for interest at the greater of one-month SOFR plus 4.6% or 7.6%, with a maturity structure extending to July 2031 or June 2032 subject to specified conditions. Debt creates a contractual claim on future resources and can impose constraints on strategic choices. It is not equivalent to a nonrepayable partnership payment, and it does not make the company debt free merely because the June balance sheet predates the transaction.
Merlintrader Health Score · $ANNX
3.20out of 5
Assessed November 9, 2026, after the third-quarter 2026 report. Weighted calculation: 3.0×30% + 4.0×30% + 2.5×20% + 3.0×10% + 3.0×10% = 0.90 + 1.20 + 0.50 + 0.30 + 0.30 = 3.20. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Balances keep their reporting dates: September 30, 2026 is the latest reported position, and the runway into 2028 assumes access to conditional facility tranches.
- Company guidance on the BLA and the Month 15 assessment is not a completed submission, a regulatory decision or a trial result.
- Shares outstanding reached 190,763,984 on November 5, 2026, with $115.2 million still available under the 2026 at-the-market programme.
- The Form 10-Q states that the FDA has indicated the generalizability package may not be sufficient to support BLA approval without additional patient data.
ANNX Stock FAQ: Annexon Questions Answered
What is the next catalyst for ANNX stock?
Annexon’s next two guided events both fall in the fourth quarter of 2026. The November 9, 2026 release puts the Data Monitoring Committee’s assessment of the ARCHER II overall Month 15 primary endpoint and the U.S. tanruprubart BLA submission, with U.S. and European FORWARD data, in that quarter. Sub-study analyses are expected in the first quarter of 2027 only if that endpoint is met; otherwise the trial continues to Month 24, with completion guided to the third quarter of 2027. Third-quarter release. ARCHER II analysis sequence.
Is Annexon’s tanruprubart FDA approved for Guillain-Barré syndrome?
No. Annexon said on November 9, 2026 that the U.S. Biologics License Application for tanruprubart is anticipated in the fourth quarter of 2026, with U.S. and European FORWARD data, while the European Marketing Authorisation Application filed in January 2026 remains under review by the European Medicines Agency. Filing, acceptance, review and approval are separate stages, and the Form 10-Q states that the FDA has indicated the generalizability package may not be sufficient without additional patient data. Form 10-Q, risk factors.
How much cash does Annexon have?
Annexon reported $213.4 million in cash, cash equivalents and short-term investments at September 30, 2026, made up of $102.4 million of cash and $111.0 million of short-term investments, against $209.2 million at June 30. Nine-month operating cash use was $143.5 million, and the company expects existing resources plus credit-facility funds to last into 2028; $150.0 million of the Oxford facility remained available subject to conditions at September 30. Form 10-Q, liquidity. Third-quarter release.
How many ANNX shares are outstanding, and can warrants add more?
Annexon reported 190,763,984 common shares outstanding on November 5, 2026, excluding 14,745,093 shares issuable on pre-funded warrants exercisable at $0.001. Nine-month at-the-market sales raised net proceeds of about $66.2 million on 12,269,877 shares across the 2024 and 2026 programmes, and $115.2 million remained available under the 2026 programme at September 30. Cover share count, warrants and ATM sales.
When does Annexon report earnings?
Annexon reported third-quarter 2026 results after the market close on November 9, 2026, covering the quarter ended September 30, 2026, and had not announced the date of its next report as of that date. The quarter produced a net loss of $51.2 million, or $0.25 per share. Third-quarter results.
What does Annexon do?
Annexon develops treatments targeting classical-complement-driven neuroinflammation, as described in its August 12, 2026 update. Late-stage candidates include vonaprument for geographic atrophy and tanruprubart for Guillain-Barré syndrome. ANX1502 is a different approach: an oral small molecule inhibiting activated C1s, with proof-of-concept development in cold agglutinin disease. Company description and development programs.
What does Annexon’s ARCHER II trial measure, and when are results expected?
ARCHER II measures confirmed loss of at least 15 best-corrected visual-acuity letters at two consecutive visits, according to Annexon’s analysis plan. All eligible patients have passed 15 months of treatment with retention at 90 per cent, and the fourth-quarter committee assessment of the overall primary endpoint precedes potential first-quarter 2027 sub-study analyses; otherwise the study may continue to Month 24, with completion targeted for the third quarter of 2027. Third-quarter release.
Did Annexon’s earlier ARCHER trial meet its primary endpoint?
The earlier ARCHER Phase 2 trial missed its primary anatomical lesion-growth endpoint, according to Annexon’s May 24, 2023 results announcement. Favorable functional vision findings, particularly with monthly treatment, motivated further development. ARCHER II prospectively tests protection against vision loss; the earlier functional signal must be evaluated alongside the primary miss. Original ARCHER primary and functional results. Prospective ARCHER II trial.
Primary sources
- November 9, 2026 — Third-quarter 2026 results: net loss of $51.2 million, cash and investments of $213.4 million, fourth-quarter BLA and Month 15 guidance
- November 9, 2026 — Form 10-Q for the quarter ended September 30, 2026: balance sheet, cash flow, share count, term loan, at-the-market sales and risk factors
- November 9, 2026 — Form 8-K carrying the third-quarter results exhibit
- October 28, 2026 — Virtual investor event on November 3 will review the ARCHER II design, patient demographics and communication of upcoming results
- October 16, 2026 — Inducement options for six new employees: 1,270,000 shares at $3.60
- September 24, 2026 — September 24: retinal meeting update
- August 12, 2026 — August 12: ARCHER II endpoint expansion
- August 12, 2026 — August 12: GBS filing guidance
- July 30, 2026 — July 30: Oxford financing
- Historical financial and development basis
- 01. ARCHER II dual primary endpoint and staged analysis, August 12, 2026
- 02. Q2 results and program update, August 12, 2026
- 03. ARCHER II registry, updated October 6, 2026
- 04. Original ARCHER Phase 2 results, May 24, 2023
- 05. Retinal congress presentation notice, September 24, 2026
- 06. SEC Form 10-Q, quarter ended June 30, 2026
- 07. Oxford credit facility, July 30, 2026
- 08. Oxford agreement and terms, Form 8-K
- 09. Current leadership and company profile
- Form 4, filed September 25, 2026
- 11. GBS pivotal topline disclosure, June 4, 2024
- 12. GBS Phase 3 design and population, 2024 scientific presentation
- 13. Official press-release archive, as of October 10, 2026
- 14. Syfovre U.S. prescribing information
- 15. Izervay U.S. prescribing information
- 16. Board changes announced August 10, 2026
- 17. September 15 option grants, announced September 16, 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ANNX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology companies carry clinical, regulatory, manufacturing, commercial and financing risks. Trials can fail, safety information can change and development timelines can slip. Additional borrowing or equity issuance can increase obligations or dilute shareholders. This page is not medical advice and does not replace a clinician or prescribing information. Investors can lose part or all of their capital. Readers are responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



